Targeting a specific protein to treat certain blood cancers
Official title: Targeting GSK3B in refractory B-cell malignancies
Funded at Yale University · NIH-10890884 · Data updated 2026-11-12
This study is looking at how a protein called GSK3B affects another protein, E-catenin, which plays an important role in certain blood cancers like acute lymphoblastic leukemia, and it aims to find new treatments using special drugs that target GSK3B to help patients with these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | July 19, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $572,454 |
| NIH project number | 5R01CA282877-02 |
| Project ID | NIH-10890884 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with refractory B-cell malignancies, particularly those who have not responded to standard treatments.
✕Less likely to help
Patients with solid tumors or those without B-cell malignancies may not benefit from this research.
What this research studies
This research investigates how a protein called GSK3B regulates another protein, E-catenin, which is crucial in the development of B-cell malignancies like acute lymphoblastic leukemia. The study aims to understand the unique interactions between E-catenin and other proteins in B-cell cancers, which differ from solid tumors. By using small molecule inhibitors that target GSK3B, the research seeks to exploit a new therapeutic approach that could lead to effective treatments for patients with these types of blood cancers.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for patients with refractory B-cell malignancies.
How similar studies have gone: Other research has shown promising results using similar approaches to target GSK3B in different cancer types, indicating potential for success in this area as well.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Müschen, Markus — Yale University
- Study coordinator: Müschen, Markus
Related research
Other NIH-funded projects on the same topics.
-
Aging Well with HIV: Alcohol, Risk Reduction, and Education Center (AWAR3E)
A center at Yale is exploring how aging with HIV interacts with alcohol use to create inflammation and frailty, with the goal of finding biomarkers and potential treatments.
-
Community Health Worker–Led Hypertension Prevention and Control in Nepal
A community health worker–driven approach in Nepal aims to prevent and control high blood pressure among adults by bringing education and care directly to communities and homes.
-
Community health worker-led hypertension prevention and control in Nepal
A community health worker–led program in Nepal aims to help adults prevent and better control high blood pressure through home visits, education, and ongoing support.
-
Adapting a mobile health tool to boost HIV outcomes for older adults with HIV in Ukraine
A mobile health platform called PositiveLinks would be adapted for older adults with HIV in Ukraine to help them stay engaged in care and improve treatment success.
-
Behavioral and neural links between spoken language sounds and written words in young children
This grant studies how young children learn from listening and reading to improve literacy, by looking at how sound patterns transfer to written language.
-
Understanding how autoimmunity causes myasthenia gravis
This project looks at why the immune system attacks the nerve-muscle connection in myasthenia gravis and how different patient groups are affected.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.